SRC and cancer: When compared to control cells, the outcome demonstrated that LIST overexpression resulted in a reduction of c‐Src (Y530) in cancer cells (cell lines 5637 and A549) and a significant advantage in tumor growth (Figure 4A, and Figures S11A and S12A, Supporting Information).